A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór lity (np. rak jajnika, płuca, piersi, żołądka), który jest zaawansowany lub rozprzestrzeniony (przerzutowy).
- •Nowotwór, który nie reaguje lub postępuje mimo dotychczasowego leczenia.
- •W niektórych przypadkach wymagane są specyficzne cechy nowotworu, np. amplifikacja genu CCNE1 lub cechy receptora HER2, estrogenowego i progesteronowego.
✗ Disqualifies
- •Pacjenci, którzy nie spełniają powyższych kryteriów kwalifikacji.
- •Pacjenci z innymi chorobami, które mogłyby wpłynąć na bezpieczeństwo lub wyniki badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (19)
University of Arkansas Medical School
Little Rock, United States
University of California - Los Angeles
Los Angeles, United States
UCSF
San Francisco, United States
SCRI at HealthOne
Denver, United States
Florida Cancer Specialists & Research Institute
Lake Mary, United States
AdventHealth Cancer Institute
Orlando, United States
Emory Winship Cancer Institute
Atlanta, United States
Augusta University
Augusta, United States
University of Kansas
Fairway, United States
Dana Farber Cancer Institute
Boston, United States
John Theurer Cancer Center at Hackensack UMC
Hackensack, United States
Sidney Kimmell Cancer Center - Jefferson Health
Philadelphia, United States
UPMC
Pittsburgh, United States
Sarah Cannon Research Institute (SCRI)
Nashville, United States
NEXT Oncology
Austin, United States
UT Southwestern
Dallas, United States
Intermountain Health
Salt Lake City, United States
University of Virginia
Charlottesville, United States
NEXT Virginia
Fairfax, United States
Trial contact
Sponsor Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.